EGFR and breast cancer: To investigate whether the Her-1/2 pathway affects TXNIP expression in human breast cancer cells, BT474 and SK-BR-3 cells were treated with 10 μg/ml cetuximab, 20 μg/ml trastuzumab or 0.5 μM lapatinib.